N-(苄亚基氨基)甲胺 | 13466-29-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(苄亚基氨基)甲胺
• 英文名称: (E)-1-benzylidene-2-methylhydrazine
• 英文别名: benzaldehyde N-methyl hydrazone；N-(benzylideneamino)methanamine；N-[(E)-benzylideneamino]methanamine
• CAS: 13466-29-0
• 化学式: C₈H₁₀N₂
• 分子量: 134.181
• InChiKey: XXCMGYNVDSOFHV-JXMROGBWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  24.4
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2928000090

反应信息

• 作为反应物：
  描述：

  N-(苄亚基氨基)甲胺 在 三氟乙酸 、 zinc(II) chloride 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 5-(2-chloro-4-methoxycarbonylmethylphenyl)-1-methyl-3-phenyl-1H-pyrazole-4-carboxylic acid
  参考文献：
  名称：

  3,4,5-Trisubstituted isoxazoles as novel PPARδ agonists. Part 2

  摘要：

  A series of PPARdelta-selective agonists was investigated and optimized for a favorable in vivo pharmacokinetic profile. Isoxazole LCI765 (17d) was found to be a potent and selective PPARdelta agonist with good in vivo PK properties in mouse (C(max)=5.1 microM, t(1/2)=3.1 h). LCI765 regulated expression of genes involved in energy homeostasis in relevant tissues when dosed orally in C57BL6 mice. A co-crystal structure of compound LCI765 and the LBD of PPARdelta is discussed.

  DOI：

  10.1016/j.bmcl.2006.08.052
• 作为产物：
  描述：

  苯甲醛 、 甲基肼 以 甲醇 为溶剂， 反应 18.0h， 以85%的产率得到N-(苄亚基氨基)甲胺
  参考文献：
  名称：

  3,4,5-Trisubstituted isoxazoles as novel PPARδ agonists. Part 2

  摘要：

  A series of PPARdelta-selective agonists was investigated and optimized for a favorable in vivo pharmacokinetic profile. Isoxazole LCI765 (17d) was found to be a potent and selective PPARdelta agonist with good in vivo PK properties in mouse (C(max)=5.1 microM, t(1/2)=3.1 h). LCI765 regulated expression of genes involved in energy homeostasis in relevant tissues when dosed orally in C57BL6 mice. A co-crystal structure of compound LCI765 and the LBD of PPARdelta is discussed.

  DOI：

  10.1016/j.bmcl.2006.08.052

文献信息

• 1,2,4-Triazole-3,5-diamine derivatives
  申请人：Glaxo Group Limited

  公开号：US04318913A1

  公开（公告）日：1982-03-09

  The invention relates to compounds of the formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in which R.sub.1 and R.sub.2 represent hydrogen, an aliphatic or cycloaliphatic group, or R.sub.1 and R.sub.2 together with the nitrogen atom form a 5 to 10 membered heterocyclic ring: Alk represents a straight or branched alkylene chain; Q represents furan, thiophen or benzene ring which is incorporated into the rest of the molecule; X represents --CH.sub.2 --, ##STR2## --O-- or --S-- where R.sub.6 represents hydrogen or methyl; n represents zero, 1 or 2; m represents 2, 3 or 4; R.sub.3 represents hydrogen, a substituted or unsubstituted aliphatic or aryl group and; R.sub.4 and R.sub.5, which may be the same or different, each represent hydrogen, a substituted or unsubstituted aliphatic, aryl, or together with the nitrogen atom form a heterocyclic group.

  该发明涉及式(I)的化合物及其生理上可接受的盐、水合物和生物前体，其中R.sub.1和R.sub.2代表氢、脂肪族或环脂族基团，或者R.sub.1和R.sub.2与氮原子一起形成5到10元杂环环：Alk代表直链或支链烷基链；Q代表噻吩或苯环，其嵌入到分子的其余部分中；X代表--CH.sub.2 --，--O--或--S--，其中R.sub.6代表氢或甲基；n代表零、1或2；m代表2、3或4；R.sub.3代表氢、取代或未取代的脂肪族或芳基团；R.sub.4和R.sub.5，可以相同也可以不同，每个代表氢、取代或未取代的脂肪族、芳基，或者与氮原子一起形成杂环基团。
• [EN] HALOGEN SUBSTITUTED DIKETONES, PYRAZOLE COMPOUNDS AND PROCESSES FOR THE MANUFACTURE OF PYRAZOLE COMPOUNDS<br/>[FR] DICÉTONES SUBSTITUÉES PAR UN HALOGÈNE, COMPOSÉS DE PYRAZOLE ET LEURS PROCÉDÉS DE PRODUCTION
  申请人：SOLVAY

  公开号：WO2017129759A1

  公开（公告）日：2017-08-03

  The present invention concerns new halogen substituted diketone compounds, new pyrazole compounds, processes for the manufacture of pyrazole compounds and processes for the manufacture of agrochemical or pharmaceutical compounds.

  本发明涉及新的卤代二酮化合物、新的吡唑化合物、制造吡唑化合物的方法以及制造农用化学品或药物化合物的方法。
• [EN] NEW TRPA1 ANTAGONISTS<br/>[FR] NOUVEAUX ANTAGONISTES DE TRPA1
  申请人：ALMIRALL SA

  公开号：WO2017060488A1

  公开（公告）日：2017-04-13

  The present invention relates to compounds of Formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by TRPA1 channel inhibition or antagonism.

  本发明涉及式(I)的化合物，以及制备这种化合物的方法，以及它们在治疗通过TRPA1通道抑制或拮抗可改善的病理状况或疾病中的用途。
• [EN] ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME<br/>[FR] COMPOSÉ ÉLECTROLUMINESCENT ORGANIQUE ET DISPOSITIF ÉLECTROLUMINESCENT ORGANIQUE LE COMPRENANT
  申请人：ROHM & HAAS ELECT MATERIALS KOREA LTD

  公开号：WO2017099516A1

  公开（公告）日：2017-06-15

  The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound according to the present disclosure is capable of producing an organic electroluminescent device with reasonably improved color purity and efficiency.

  本公开涉及一种有机电致发光化合物和包括该化合物的有机电致发光器件。根据本公开的有机电致发光化合物能够制备出具有较好色纯度和效率的有机电致发光器件。
• [EN] COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSÉS ET COMPOSITIONS EN TANT QU'INHIBITEURS DE PROTÉINE KINASE
  申请人：IRM LLC

  公开号：WO2011025927A1

  公开（公告）日：2011-03-03

  The invention provides a novel class of compounds of formula 1, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

  这项发明提供了一类新型的化合物，其化学式为1，包括这些化合物的药物组合物以及使用这些化合物来治疗或预防与异常或失调的激酶活性相关的疾病或障碍的方法，特别是涉及B-Raf异常激活的疾病或障碍。